ABRYSVO's Patent Review Period Locked In by FDA
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for ABRYSVO, a new human biological product. This means the company can apply to extend its patent, giving them more time to protect their invention. If approved, this could affect when generic versions hit the market and impact future drug prices.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA Sets Review Period for ABRYSVO
The FDA has determined the regulatory review period for ABRYSVO, a human biological product. The company submitted an application to the U.S. Patent and Trademark Office to extend a patent that claims ABRYSVO, allowing the company to seek additional time to protect its invention.
Possible Delay of Generics and Price Effects
If the patent extension for ABRYSVO is approved, it could delay when generic versions reach the market and could affect future drug prices. This change would influence when patients and buyers can access lower-cost alternatives.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in